Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 StudyEvan C. Chen, Jacqueline S. Garcia, Marlise R. Luskin et al.|Blood|2024Cited by 3
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemiaEmma-Jayne Minihane, Jacqueline S. Garcia, Leah Krotee et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1